Aeglea BioTherapeutics | Results Presentation Deck | 23 slides

Aeglea BioTherapeutics · 2021-12
arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 1
No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.

Deck intelligence map

3
coverage by narrative range · generated from this deck JSON

Slide inventory

23
every slide · same image gating as the playbook
01
Slide 1
front_matter
03
The slide features three photos representing the research team, clinical collaboration, and the patient community.summarize
04
front_matter
05
The slide uses a structured layout to present three key pillars of clinical success: efficacy, functional outcome, and safety.summarize
Open slide detailBeat · SolutionLoop · Jobs To Be Done
06
The slide uses a process flow diagram to illustrate the clinical trial phases (randomization, treatment, extension).present_framework
Open slide detailBeat · SolutionLoop · Jobs To Be Done
07
analyze_data
Open slide detailBeat · SolutionLoop · Jobs To Be Done
08
The table displays mean, standard deviation, median, and range for various clinical metrics including Plasma Arginine, GMFCS level, GMFM-E, and 2MWT.analyze_data
Open slide detailBeat · SolutionLoop · Jobs To Be Done
09
The chart is a box-and-whisker plot comparing pegzilarginase and placebo groups against clinical guidelines and normal ranges.analyze_data
Open slide detailBeat · SolutionLoop · Jobs To Be Done
10
Clinical trial data showing efficacy of pegzilarginase.analyze_data
Open slide detailBeat · SolutionLoop · Jobs To Be Done
11
The slide contrasts unaided mobility assessment (GMFM) with aided mobility assessment (2-Minute Walk Test).present_framework
Open slide detailLoop · Jobs To Be Done
12
GMFM-E refers to Gross Motor Function Measure, dimension E (walking, running, jumping).analyze_data
Open slide detailLoop · Jobs To Be Done
13
The chart shows positive improvement for Pegzilarginase at both time points, while Placebo shows a decline at 12 weeks and slight improvement at 24 weeks.analyze_data
Open slide detailLoop · Jobs To Be Done
14
The slide uses a clear comparison table to demonstrate safety outcomes.analyze_data
Open slide detailLoop · Jobs To Be Done
15
The slide uses a three-part structure to summarize clinical trial outcomes.summarize
Open slide detailLoop · Jobs To Be Done
16
The slide uses a three-column layout to categorize program strengths.summarize
17
diagnose_problem
Open slide detailBeat · ProblemLoop · Cost Of Inaction
18
size_opportunity
Open slide detailBeat · AgitateLoop · Cost Of Inaction
19
summarize
20
summarize
21
The slide uses a Gantt-style chart to represent clinical trial phases for different drug programs.present_solution
22
state_next_steps
23
front_matter